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Chronic obstructive pulmonary disease (COPD) is a debilitating lung disease characterized by airﬂow
limitation and chronic inﬂammation in the lungs. The mainstay of drug therapy for COPD is represented
by long-acting bronchodilators, an important aspect of Novartis’ development program. Novel once-daily
dosing bronchodilators, such as the long-acting muscarinic antagonist (LAMA) glycopyrronium and the
LAMA/long-acting b2-agonist (LABA) ﬁxed-dose combination QVA149, have been shown to provide
signiﬁcant beneﬁts to patients with COPD in terms of improvement in lung function, exercise tolerance,
health-related quality of life, symptoms and reduction in the rate of exacerbations. Despite the beneﬁts
provided by these new treatment options, prevention of disease progression and control of exacerbations
in certain patient phenotypes remain key challenges in the treatment of COPD. In order to address these
needs and gain new insights into the complexity of COPD, Novartis is, in addition to bronchodilator-only
therapies, developing LABA/inhaled corticosteroids (ICS) combinations to target inﬂammation, such as
QMF149, as well as non-steroid based anti-inﬂammatory agents against key novel targets. These com-
mitments are central to the Novartis’ ﬁnal goal of improving the standard of care in respiratory medicine
and offering a better quality of life to patients with COPD.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction
Chronic obstructive pulmonary disease (COPD) is a debilitating
lung disease characterized by airﬂow limitation that is usually
progressive and associated with an enhanced inﬂammatory
response to noxious particles and gases [1]. COPD is a multicom-
ponent disease characterized by a range of pathological changes,
which include mucus hypersecretion, airway narrowing and loss of
alveoli in the lungs, and loss of lean body mass and cardiovascular
effects at a systemic level [2].
Bronchodilators are the mainstay of pharmacological therapies
for COPD. The recent revision to the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) strategic document recommends
long-acting inhaled bronchodilators as ﬁrst-line maintenance
therapy for COPD [1]. Treatment options include long-acting
muscarinic antagonists (LAMAs) and long-acting b2-agonists
(LABAs), which could be used as monotherapy or in combinations UK Limited, Wimblehurst
1403 324285; fax: þ44 1403
ompton).
r Ltd. Open access under CC BY-NC-SAfor patients whose symptoms are not effectively controlled by
single bronchodilators. Inhaled glucocorticosteroids (ICS), which
are associated with several side effects, including increase risk of
pneumonia, osteoporosis and early onset of diabetes [3], are rec-
ommended only as add-on therapy in patients with severe and very
severe COPD and frequent exacerbators that are not controlled by
long-acting bronchodilators [1]. Given the importance of long-
acting bronchodilators in the management of COPD as mono- or
combination therapy, Novartis has made such agents a key part of
its development program. As complex inhaler devices and a
frequent dosing schedule may contribute to poor adherence [4,5],
Novartis has focused its effort on trying to provide patients with
new agents with a prolonged duration of action, which permits
once-daily dosing, as well as ﬁxed-dose combinations of broncho-
dilators and bronchodilators/ICS in a single, easy-to-use inhaler,
with the aim of simplifying COPD management.
Despite the important beneﬁts provided by new treatment op-
tions to patients with COPD, there are no currently available ther-
apies able to ensure full symptom control and more remains to be
achieved to optimize quality of life. In addition, control and pre-
vention of exacerbations continue to be major challenges that need
to be further addressed in order to slow decline in lung function
and disease progression, while potentially reducing mortality.
Novartis is committed to addressing these unmet needs by license.
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of care in respiratory medicine.
This review will summarize the therapeutic advances and
beneﬁts provided by new long-acting bronchodilators developed
by Novartis as mono- or combination therapy, and discuss the most
promising targets in COPD beyond bronchodilation.
2. Long-acting bronchodilators
2.1. Currently available long-acting bronchodilators for the
treatment of COPD
Long-acting bronchodilators are the preferred option for main-
tenance treatment of COPD [1]. Two classes of long-acting inhaled
bronchodilators are available e LABAs and LAMAs. LABAs directly
induce bronchodilation by relaxing airway smooth muscle through
stimulation of b2-receptors, whereas LAMAs prevent acetylcholine-
induced bronchoconstriction by acting as competitive antagonists
on muscarinic receptors [6].
Until recently, the twice-daily LABA salmeterol and formoterol
were widely used maintenance bronchodilators. Indacaterol, the
ﬁrst once-daily LABA providing 24-hour bronchodilation, was
developed by Novartis and has been available for use in patients
with COPD since 2009. The efﬁcacy of indacaterol in improving lung
function has been demonstrated in four pivotal trials [7e10] and
several supportive Phase III studies [11e13]. Indacaterol has also
been shown to improve several important clinical outcomes; when
compared with the twice-daily LABAs salmeterol and formoterol,
indacaterol produced signiﬁcantly superior improvements in dys-
pnea and reduced the use of rescue medication [7,10,12]. Several
studies have also shown that indacaterol improves health status
and exercise endurance time and reduces the frequency of COPD
exacerbations compared with placebo [14e16]. In addition to
improving several meaningful clinical outcomes, indacaterol, with
its once-daily dosing, simpliﬁed the management of COPD,
providing a signiﬁcant advantage over previously available twice-
daily LABAs.
Tiotropium was the ﬁrst once-daily LAMA marketed for the
treatment of COPD. Despite being effective in improving a range of
important clinical outcomes [17e22], a study in patients with sta-
ble COPD has shown that tiotropium has a relative slow onset of
action, taking up to 3 h to achieve optimal bronchodilation, in
particular after the ﬁrst administration [23].
2.2. Glycopyrronium: a new long-acting muscarinic antagonist for
the treatment of COPD
The once-daily LAMA glycopyrronium bromide (NVA237) has
recently been approved as a once-daily treatment for COPD. Like
other LAMAs, glycopyrronium acts as a competitive antagonist by
binding to muscarinic type-1 (M1) and type-3 (M3) receptors in the
bronchial smooth musculature, thereby preventing acetylcholine-
induced bronchoconstriction [24]. Blockade of muscarinic type-2
(M2) receptors, which modulate cardiac sinus activity and
contraction force in the heart [25], has the potential to cause car-
diac side effects. It has been shown that glycopyrronium has a
higher kinetic selectivity for M3 versus M2 receptors than tio-
tropium and a shorter residence time than tiotropium on M1 re-
ceptors, which are expressed in exocrine glands and central
nervous system and are associated with anticholinerigic adverse
events such as dry mouth and gastrointestinal disturbances [26]. In
preclinical studies, glycopyrronium displayed an improved in vivo
therapeutic index, particularly for cardiovascular side effects,
compared with tiotropium [27]. Notably, glycopyrronium also dis-
played a rapid onset of action in vitro, with a half-life (t1/2) of6.1  2.1 min for inhibition of methacholine-induced calcium
release e approximately ﬁve times faster than that of tiotropium
(t1/2 29.4  4.2 min) [26]. Taken together, these results suggested
potential for a more favorable tolerability proﬁle and faster onset of
action for glycopyrronium versus tiotropium, providing the ratio-
nale for further investigating glycopyrronium in clinical trials.
Phase II studies have shown that once-daily glycopyrronium
(12.5e200 mg) is well tolerated and provides sustained 24-hour
bronchodilation in patients with moderate-to-severe COPD [28e
30]. The Phase III GLycopyrronium bromide in COPD airWays
(GLOW) program further evaluated the efﬁcacy and safety of 50 mg
glycopyrronium once daily (50 mg refers to the quantity of the
glycopyrronium moiety present in the capsule, which corresponds
to a delivered dose of 44 mg) taken in the morning in patients with
moderate-to-severe COPD. GLOW1 evaluated the efﬁcacy, safety
and tolerability of glycopyrronium compared with placebo over 26
weeks. GLOW2 evaluated the efﬁcacy and safety of glycopyrronium
compared with placebo and open-label (OL) tiotropium 18 mg once
daily (as an active comparator) over 52 weeks and GLOW3 assessed
the effects of glycopyrronium versus placebo on exercise tolerance.
2.2.1. Lung function
In GLOW1 FEV1 atWeek 12 (primary endpoint) was signiﬁcantly
higher in patients receiving glycopyrronium compared with pa-
tients receiving placebo, with a least squares means (LSM) treat-
ment differences versus placebo of 108 mL (p < 0.001; Fig. 1A) [31].
Similarly, in GLOW2 glycopyrronium signiﬁcantly improved trough
FEV1 at Week 12 (primary endpoint) versus placebo, with a LSM
treatment difference of 97 mL (p < 0.001; Fig. 1B) [32]. The efﬁcacy
of glycopyrronium versus placebo in lung function improvement
was similar to that of OL tiotropium (83 mL versus placebo
p < 0.001; Fig. 1B). The bronchodilation achieved with glyco-
pyrronium was sustained over 26 weeks (GLOW1) and 52 weeks
(GLOW2) (Fig. 1A and B).
2.2.2. Onset of bronchodilation
In addition to being as effective as OL tiotropium in improving
lung function, glycopyrronium displayed a rapid onset of action on
Day 1. In GLOW1, a signiﬁcant increase in FEV1was already apparent
shortlyafter theﬁrst dose onDay1,with a difference inmeanFEV1 of
93 mL at 5 min and 144 mL at 15 min versus placebo (p < 0.001). In
GLOW2, the mean FEV1 treatment difference on Day 1 for glyco-
pyrronium versus placebo was 87 mL at 5 min post-dose, while the
difference for OL tiotropium versus placebo was 45 mL at 5 min (all
p< 0.001). FEV1 was signiﬁcantly higher at all measured timepoints
from 5min to 4 h post-dose comparedwith placebo (p< 0.001) and
OL tiotropium (p< 0.01) (Fig. 2). In GLOW2onDay 1 and atWeek 26,
glycopyrroniumproduced early bronchodilation followingmorning
dosing,with signiﬁcantly greater peak FEV1 and FEV1 area under the
curve (AUC) from 0 to 4 h (AUC0e4 h) post-dose compared with
tiotropiumandplacebo. The peak FEV1 LSM treatment difference for
glycopyrronium-placebo and tiotropium-placebo was 200 and
152 mL (p < 0.001) at Day 1 and 177 and 127 mL at Week 26,
respectively (p < 0.001); the treatment difference for glyco-
pyrroniumversus tiotropiumwas47mL (p<0.001). The FEV1AUC0e
4 h LSM treatment difference for glycopyrronium-placebo and
tiotropium-placebo was 197 mL and 141 mL at Day 1 and 177 and
127 mL at Week 26 (all p < 0.001); the treatment difference for
glycopyrronium versus tiotropium was 56 and 50 mL at Day 1 and
Week 26, respectively (p < 0.001 and p < 0.01).
This rapid and early onset of bronchodilation of glycopyrronium
compares favorably against tiotropium. The rapid onset of action of
glycopyrronium could have important implications in COPD, as it
may provide early relief of morning symptoms, a recognized issue
for patients [33]. This may result in improvement in the ability to
AA
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Fig. 1. Glycopyrronium steady state improvement in trough FEV1 achieved on Day 1
and sustained until (A) Week 26 (GLOW1) [31] and (B) Week 52 (GLOW2) [32]. Data
are least squares means (LSM)  standard errors (SE); *p < 0.001 versus placebo;
yp ¼ 0.007 versus tiotropium; FEV1 ¼ forced expiratory volume in 1 s.
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analysis investigating the impact of morning symptoms in patients
receiving an ICS/LABA ﬁxed-dose combination has recently shown
that patients with morning symptoms had signiﬁcantly more ex-
acerbations in the previous twelve months than those without
(p ¼ 0.005) [34].Fig. 2. FEV1 at each timepoint up to 4 h post-dose on Day 1: GLOW2 [32]. Data are
least square means; p < 0.001 for glycopyrronium and tiotropium versus placebo at all
timepoints 5 min to 4 h; p < 0.01 for glycopyrronium versus tiotropium at all time-
points 5 min to 4 h; FEV1 ¼ forced expiratory volume in 1 s.2.2.3. Symptoms and health-related quality of life
In both GLOW1 and GLOW2, glycopyrronium also signiﬁcantly
reduced symptoms such as breathlessness, one of the cardinal
symptoms of COPD, as measured by the transition dyspnea index
(TDI). In GLOW1, glycopyrronium signiﬁcantly improved TDI focal
score at Week 26, with a treatment difference of 1.04 versus pla-
cebo (p < 0.001), which exceeded the 1-point treatment difference
considered as clinically important (Fig. 3A) [35]. In GLOW2, both
glycopyrronium and tiotropium signiﬁcantly improved TDI focal
scores compared with placebo at Week 26 with treatment differ-
ences of 0.81 and 0.94, respectively (both p ¼ 0.002) (Fig. 3B).
In both studies glycopyrronium improved health-related quality
of life, as assessed by the St George’s Respiratory Questionnaire
(SGRQ). In GLOW1, the SGQR total score was signiﬁcantly better
(lower) in patients receiving glycopyrronium compared with pla-
cebo (p ¼ 0.004) at Week 26, with a treatment difference of 2.81.
A signiﬁcantly higher percentage of patients achieved a clinically
meaningful improvement in SGRQ (4-point reduction) with gly-
copyrronium compared with placebo (OR 1.58, 95% CI: 1.14;
p ¼ 0.006). At Week 52 in GLOW2, SGRQ total score was signiﬁ-
cantly improved in patients receiving glycopyrronium and OL tio-
tropium versus placebo, with treatment differences of 3.32
(p < 0.001) and 2.84 (p ¼ 0.014). A numerically higher proportion
of patients receiving glycopyrronium or OL tiotropium achieved
clinically meaningful improvements in SGRQ compared with
placebo.
2.2.4. Exacerbations
Glycopyrronium signiﬁcantly reduced the risk of a ﬁrst moder-
ate or severe exacerbation by 31% compared with placebo over 26
weeks in GLOW1 (p ¼ 0.023) and by 34% over 52 weeks in GLOW2
(p < 0.001; Fig. 4). In the GLOW2 study, the risk reduction versusB
Fig. 3. Improvements in dyspnea with glycopyrronium versus placebo in GLOW1 [31]
(A) and GLOW2 (B) [32]. Data are least squares (LS) means  standard errors (SE);
TDI ¼ Transition Dyspnea Index. *p < 0.01.
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tropium (Fig. 4).
2.2.5. Exercise tolerance
In GLOW3, morning dosing of glycopyrronium improved exer-
cise endurance time measured 1 h post-dose by 10% on Day 1 and
21% on Day 21 versus placebo (p < 0.001; Fig. 5) [36]. This was
accompanied by sustained reductions in lung hyperinﬂation, as
indicated by signiﬁcant improvements in inspiratory capacity (IC)
at isotime (Fig. 5), which was also seen in the longer GLOW1 and
GLOW2 studies. Glycopyrronium was also found to reduce exer-
tional dyspnea versus placebo 1 h post-dose on Day 1 and Day 21
(p < 0.05; Fig. 5) as measured by the Modiﬁed Borg Dyspnea score
at isotime.
2.2.6. Safety
Pooled data of GLOW1 and GLOW2 demonstrated that glyco-
pyrronium was well tolerated with a low frequency of cardiac and
antimuscarinic side effects which was comparable to that of pla-
cebo and OL tiotropium. Antimuscarinic side effects, such as dry
mouth, gastrointestinal disturbances, urinary retention and urinary
tract infections, occurred with a low frequency in the glyco-
pyrronium, placebo and tiotropium treatment groups. The per-
centage of patients with newly occurring or worsening clinically
notable QTcF values (QT interval with Fridericia’s correction) was
low across all treatment groups. The number of deaths reported in
each group was low and similar across treatments, and none were
considered to be related to study medication.
2.2.7. Glycopyrronium as an alternative choice to tiotropium
Overall, these results suggest that glycopyrronium is well
tolerated and as effective as tiotropium in improving lung function,
health status and exercise tolerance, and reducing dyspnea and risk
of exacerbations in patients with COPD. Glycopyrronium, with its
fast onset of action, represents a useful alternative to tiotropium.
3. Combination therapy in COPD
3.1. Combining long-acting bronchodilators
A single bronchodilator may not be optimal for COPD manage-
ment especially for patients whose symptoms are not effectivelyFig. 4. Glycopyrronium prolong time to ﬁrst COPD exacerbation (modcontrolled by monotherapy. As previously mentioned, the GOLD
2013 update recommends combination therapy with LAMA and
LABA to optimize symptoms beneﬁts [1].
Although the nature of interaction between cholinergic and
adrenergic pathways in airway smooth muscle has not been fully
understood, there is pharmacological evidence to suggest that the
combination of muscarinic antagonists and b2-agonists could have
an additive effect on bronchodilation. The activation of b2-receptors
with a b2-agonist reduces release of Ach by modulating cholinergic
neurotransmission [37e39] thereby amplifying the bronchodila-
tion produced by muscarinic antagonists [6]. b2-receptors are
abundant in the small airways [40], whereas M3 receptors are
predominantly found in the lower trachea and bronchi [41]. Thus,
the combination of b2-agonists and muscarinic antagonists could
result in a better coverage of the airways compared with mono-
therapy and provide maximal bronchodilation in all regions of the
human lungs.
LABA/LAMA combinations have been shown to improve lung
function (formoterol plus tiotropium [42e44]; tiotropium plus
indacaterol [45]), symptoms and reduce the need for daytime
rescue medication compared with monotherapy (formoterol plus
tiotropium [42e44]). Safety data from all these studies have sug-
gested that combination therapy does not increase the risk of side
effects compared with monotherapy. In addition to providing
greater bronchodilation, ﬁxed-dose combinations of LABAs and
LAMAs may simplify treatment and potentially lead to increased
adherence, particularly for patients with several comorbities who
are likely to be taking other medications.
Given these multiple potential beneﬁts, QVA149 is currently in
development at Novartis as a once-daily ﬁxed-dose combination of
the established LABA indacaterol and the new efﬁcacious LAMA
glycopyrronium, administered in a single inhaler, which affords the
additional beneﬁt of simplifying treatment regimens and hence
opportunity to improve adherence.
3.2. QVA149 (indacaterol/glycopyrronium)
Although several LABA/LAMA combinations are currently under
investigation [46], QVA149, which contains a ﬁxed-dosed combi-
nation of indacaterol (110 mg) and glycopyrronium (50 mg), is the
once-daily dual bronchodilator in the most advanced stage of
development. In a Phase II study, QVA149 had a rapid onset oferate-to-severe) compared with placebo 52 weeks (GLOW2) [32].
A B
C
Fig. 5. Improvements in (A) exercise endurance, (B) lung function during exercise and (C) exertional dyspnea after 3 weeks of treatment with glycopyrronium versus placebo:
GLOW3 [36]. IC ¼ inspiratory capacity. Data are LSM either SE or 95% CI. *p < 0.05; ***p < 0.001 versus placebo.
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compared with placebo and indacaterol alone on Day 1 and Day 7
[47]. In a study primarily designed to assess cardiovascular safety,
QVA149 was tolerated with an adverse event (AE) rate similar to
that of placebo [48].
QVA149 is undergoing investigation in the ongoing IGNITE
clinical trial program, one of the largest Phase IIIa program in COPD
involving more than 7000 patients with moderate-to-severe COPD
[49]. The IGNITE program is evaluating the safety and efﬁcacy of
QVA149 on lung function, rate of exacerbations, exercise endurance
and dyspnea, versus indacaterol, glycopyrronium, tiotropium, sal-
meterol/ﬂuticasone (SFC) and placebo.
SHINE, a 26-week, double-blind, parallel-group study was
designed to compare QVA149 with placebo, indacaterol 150 mg,
glycopyrronium 50 mg and OL tiotropium 18 mg in 2144 patients
with moderate-to-severe COPD [50]. QVA149 signiﬁcantly
improved trough FEV1 at Week 26 (primary endpoint) compared
with placebo and all active treatments (mean difference versus
placebo, indacaterol, glycopyrronium and tiotropium: 200, 70, 90
and 80 mL, respectively; all p < 0.001; Table 1). QVA149 provided
24-hour bronchodilationwith a rapid onset of action from Day 1, as
shown by signiﬁcantly higher FEV1 and FEV1 AUC0e4 h compared
with placebo and all the active comparators (all p < 0.01; Table 1).
At Week 26, TDI focal score was signiﬁcantly improved with
QVA149 compared with placebo (LSM difference 1.09; p < 0.001)
and tiotropium (LSM difference 0.51; p< 0.05; Table 1). AtWeek 26,
QVA149 also signiﬁcantly improved SGRQ total score versusplacebo (LSM difference 3.01; p < 0.01) and tiotropium (LSM
difference 2.13; p < 0.05; Table 1).
In the ILLUMINATE study, QVA149 was compared with the
LABA/ICS combination of twice-daily SFC in terms of efﬁcacy, safety,
and tolerability in patients with moderate-to-severe COPD and no
history of exacerbations in the previous year [51]. This particular
patient population was chosen to provide new evidence to support
the recommended approach of treating patients with moderate-to-
severe COPD with bronchodilators, while reserving ICS for patients
with severe disease and high risk of exacerbation. Despite this
recommendation, the side effects associated with their use, and
their relative narrow approved indications in many countries,
combination inhalers containing ICS are often prescribed to pa-
tients with more moderate disease [52]. The results of this study
highlighted the potential beneﬁts of dual bronchodilation over
LABA/ICS combination in patients with moderate-to-severe COPD.
FEV1 AUC from 0 to 12 h (AUC0e12 h) was signiﬁcantly higher with
QVA149 versus SFC at Day 1 and Weeks 12 and 26 (primary
endpoint) (LSM difference: 70,120 and 140, respectively; p< 0.001;
Fig. 6). Serial spirometry showed signiﬁcantly higher and clinically
meaningful improvements in FEV 1 with QVA149 versus SFC at all
timepoints from 0 to 12 h at Day 1 andWeeks 12 and 26 (p < 0.001
at all timepoints). QVA149 signiﬁcantly improved the TDI focal
score versus SFC (treatment mean: 2.16 versus 1.41; p ¼ 0.003) and
reduced the use of rescue medication.
In the BRIGHT study, QVA149 also improved exercise tolerance
versus placebo in patients with moderate-to-severe COPD [53].
Table 1
Improvements in lung function, symptoms, health-related quality of life and rescue medication use with QVA149 versus placebo, indacaterol, glycopyrronium and tiotropium:
the SHINE study [50].
Least squares mean treatment difference
Day 1 QVA149ePBO QVA149eIND QVA149eNVA237 QVA149eTIO
Trough FEV1 (mL)þ 190a 80a 80a 80a
FEV1 AUC0e4 h (mL) 220a 60a 30a 80a
Week 26
Trough FEV1 (mL) 200a 70a 90a 80a
FEV1 AUC0e4 h (mL) 340a 110a 140a 130a
FEV1 AUC0e24 h (mL) 320a 110a 110a 110a
Peak FEV1 (L) (0e4 h) 330a 120a 130a 130a
Transition Dyspnea Index focal score 1.09a 0.26 0.21 0.51c
St George’s Respiratory Questionnaire
total score
3.01b 1.09 1.18 2.13c
Rescue medication use 0.96a 0.30c 0.66c 0.54c
þ End of Day 1; a p < 0.001; b p < 0.01; c p < 0.05. FEV1 ¼ forced expiratory capacity in 1 s; AUC0e4 h ¼ area under the curve (AUC) from 0 to 4 h; AUC0e24 h ¼ area under the
curve (AUC) from 0 to 24 h.
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2224 patients over a period of 64 weeks, showed that QVA149
reduced the risk of moderate/severe exacerbations by 12%
compared with glycopyrronium (primary endpoint; p < 0.05) and
the risk of all (mild, moderate and severe) exacerbations versus
both glycopyrronium and tiotropium (p ¼ 0.001 and p < 0.01,
respectively) [54].
Overall, these studies demonstrated that QVA149 provides a
signiﬁcant advantage versus LABA and LAMA monotherapy in
terms of improvement in lung function, relief from symptoms and
reduction in the number of exacerbations. In addition, there were
incremental beneﬁts in lung function, dyspnea and rescue medi-
cation use compared to LABA/ICS combination therapy in patients
without history of an exacerbation in the previous year, therefore
highlighting the importance of dual bronchodilation in moderate-
to-severe COPD.Fig. 6. Improvement in lung function with QVA149 versus SFC: the ILLUMINATE study [5
comparisons between QVA149 and SFC; AUC0e12 h ¼ area under the plasma concentrat
SFC ¼ salmeterol/ﬂuticasone. n numbers shown represent patient number per treatment g3.3. ICS/LABA combinations
The use of ICS plus LABA therapy is recommended in patients
with severe COPD and high risk of exacerbation [1]. In contrast to
their effectiveness in controlling the underlying chronic inﬂam-
mation in asthma, the efﬁcacy of ICS in COPD is less well established
and the debate over their clinical use continues. Evidence from a
number of clinical trials suggest that ICS as monotherapy failed to
prevent disease progression in patients with COPD [55e57]. Several
long-term clinical studies have shown that high-dose ICS had no
effect on the annual decline of FEV1 [55,57]. A meta-analysis of six
long-term studies, involving 3571 patients with COPD, also failed to
show any effect on the rate of FEV1 decline [55,56]. The limited
efﬁcacy of ICS treatment in COPD could be explained by its inability
to suppress inﬂammation in lungs and airways due to an active
resistance mechanism [58].1]. Data are LSM  SE; FEV1 ¼ forced expiratory volume in 1 s; ***p < 0$0001 for
ionetime curve from 0 to 12 h; LSM ¼ least squares means; SE ¼ standard error;
roup at each timepoint.
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shown a greater clinical effect when used in combination with
long-acting bronchodilators. The TORCH (Towards a Revolution in
COPD Health) study compared all-cause mortality among patients
with COPD between SFC, ﬂuticasone propionate, salmeterol, and
placebo [59]. Although not effective in reducing mortality, SFC
provided greater symptom control, improvement in pulmonary
function and reduction in exacerbations, compared with either of
the individual components [59]. A post hoc analysis of the results of
this study showed a small but signiﬁcant reduction in the annual
rate of FEV1 decline by SFC compared with placebo in severe pa-
tients [60], suggesting that the use of ICS/LABA combination could
potentially have a positive impact on disease progression. More-
over, ICS/LABA combinations appear to have anti-inﬂammatory
effects not seen with ICS alone [61]. ICS have also been shown to
enhance the bronchodilator effect of LABAs [62], suggesting that
additional pro-contractile agents, the release of which could be
mediated by the activation of pro-inﬂammatory pathways, may
contribute to the airﬂow limitation observed in COPD. Even though
the molecular mechanism of such a synergistic effect is yet fully
understood, it is now acknowledged that the pathways activated by
ICS and LABAs interact at several different levels [63].
In light of these ﬁndings, complementing the bronchodilator
effect of LABAs with adjunctive ICS therapy is a valuable option for
patients with more severe COPD and frequent exacerbations. In
order to meet the treatment needs of these patients, Novartis is
investing signiﬁcant resources in developing QMF149, a new ICS/
LABA combination.
3.4. QMF149 (indacaterol/mometasone)
QMF149, administered via the Breezhaler device, is a once-
daily ICS/LABA ﬁxed-dose combination of mometasone furoate
and indacaterol currently in development at Novartis for the
maintenance treatment of asthma and COPD. Although in early
stages of clinical development for the treatment of COPD, QMF149
with its once-daily dosing has the potential to provide important
beneﬁts over the two currently available twice-daily ICS/LABA
ﬁxed-dose combinations ﬂuticasone propionate/salmeterol and
budesonide/formoterol. In addition, evening dosing is expected to
ensure peak efﬁcacy of QMF149 during early morning hours when
lung function and symptoms are worst [33].
This new ICS/LABA combination could also represent an advance
in therapy as it combines the efﬁcacy and rapid onset of action of
the established LABA indacaterol with the anti-inﬂammatory ac-
tivity of mometasone furoate. Mometasone furoate, alone or in
combination with formoterol, is licensed for the treatment of
asthma and COPD, where it has been shown to have a favorable
safety and tolerability proﬁle [64e66]. In a 52-week, placebo-
controlled clinical trial in patients with COPD, mometasone furo-
ate signiﬁcantly increased FEV1 from baseline and reduced the risk
of exacerbations [67]. The study demonstrated comparable AE rates
between mometasone furoate and placebo groups, with a low
incidence of pneumonia, a side effect associated with some ICS/
LABA combinations [68].
The efﬁcacy and safety of QMF149 via the Twisthaler device
was assessed in a randomized, double-blind, active-comparator
(mometasone furoate) study in patients with persistent asthma
[69,70]. QMF149 signiﬁcantly improved trough FEV1 and reduced
the risk of a serious exacerbation versus mometasone furoate with
an incidence of AEs comparable to that of mometasone furoate
alone. The efﬁcacy and safety of QMF149 (150 mg/160 mg once-daily)
compared with salmeterol xinafoate/ﬂuticasone propionate (50 mg/
500 mg twice-daily) will be investigated in a randomized, double-
blind, 12-week parallel group study in patients with moderate-to-very severe COPD [71]. The Twisthaler device has been replaced
by the Breezhaler device, which is able to ensure a higher lung
delivery [72], in the QMF149 development program.
3.5. The Breezhaler device: a common platform for the delivery of
Novartis COPD pipeline products
As inhalation is the preferred route of administration in COPD,
the characteristics of inhalation devices play a vital role in ensuring
an effective management of this disease. An ideal inhaler for use in
COPD should be easy to use and provide optimal and consistent
drug delivery over a wide range of inspiratory ﬂow rates. The in-
ternal resistance of the inhaler determines the effort patients have
to make to achieve adequate inspiratory ﬂows for effective and
reproducible dose delivery [73,74]. This is particularly relevant in
light of the results of recent studies showing that older patients and
those with severe COPD have difﬁculty generating sufﬁcient
inspiratory ﬂow for correct use of dry-powder inhalers [75,76]. In
order to overcome these limitations, Novartis has chosen to deliver
all its COPD products by a low-resistance single-dose, dry-powder
inhaler known as the Breezhaler device. Studies with the
Breezhaler device have shown that it delivers a consistent dose of
indacaterol, irrespective of disease severity and is easy to use and
well accepted by patients [77,78].
In addition to the characteristics mentioned above, an ideal
inhaler for use in COPD should also generate optimal particle size for
lung delivery and retention at the required site. The aerodynamic
size of drug particles generated by inhalers is one of the most
important factors in deﬁning the distribution anddeposition of drug
within the lung, with a particle size of less than 4.7 mm in diameter
generally considered optimal for deposition in the bronchi and
alveoli [79]. A high ﬁne particle fraction (FPF), deﬁned as fraction of
particles of less than 4.7 mm in diameter, indicates that a signiﬁcant
proportion of the inhaled dose is likely to reach the pulmonary re-
gion [80]. A recent in vitro study has also revealed that the
Breezhaler device delivers a high FPF across a wide range of
inspiratory ﬂows, further suggesting that it may be suitable for pa-
tients with COPD of different severities, including severe COPD [81].
The Breezhaler device also offers continuity across the Novartis
COPD portfolio, as it will be used to deliver glycopyrronium,
QVA149 and QMF149. This will simplify the management of COPD,
as patients will not need to learn the use and handling of a new
device when switching from one inhaled treatment to another.
4. Emerging anti-inﬂammatory strategy for COPD
4.1. Role of inﬂammation in COPD
Inﬂammation in the lungs leads to the airway structural changes
and associated airﬂow limitation characteristic of COPD (Fig. 7)
[82]. Macrophages and epithelial cells in the respiratory tract are
activated by inhaled irritants, such as cigarette smoke, occupational
dust and environmental pollution, to release inﬂammatory medi-
ators, including tumor necrosis factor (TNF)-a and other CXC che-
mokines, which in turn attract different types of inﬂammatory cells
to the airways [82]. Neutrophils produce proteases, which are
potent stimulants of mucus secretion [83], and are believed to be
associated with chronic bronchitis, one of the main features of
COPD. T-lymphocytes, which have the capacity to cause cytolysis
and apoptosis of alveolar epithelial cells [84], contributes to the
emphysema associated with COPD [85]. Macrophages not only
orchestrate the inﬂammatory response in COPD, but can also cause
emphysema by producing elastolytic enzymes, such as matrix
metallopeptidase 9 (MMP-9) [86], able to break down connective
tissue in the lung parenchyma.
Fig. 7. Inﬂammatory response in COPD. Adapted from Ref. [146].
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intimately linked to inﬂammation, both locally and systemically. The
number of inﬂammatory cells in bronchial biopsies and induced
sputum has been correlated with COPD disease severity and rate of
decline in lung function and health status [87e89]. Inﬂammatory
cells and mediators have also been shown to increase during an
exacerbation [90e92], suggesting that treatments that suppress
inﬂammation in COPD could potentially reduce exacerbations. In
addition, several studies have shown that serum biomarkers of
inﬂammation including TNF-a andMMP-9 are increased in patients
with COPD and correlate with the degree of airﬂow obstruction as
well as with important clinical outcomes including mortality [93e
95]. This may account for the observation that patients with COPD
also present with systemic symptoms and comorbid conditions,
including muscle weakness, weight loss, cardiovascular disease,
osteoporosis, hypertension, depression, cognitive decline [96,97].
Given the central role played by inﬂammation in COPD, target-
ing relevant pathways is key to developing innovative therapies, in
particular to slow disease progression and better control exacer-
bations. In order to achieve these goals, the identiﬁcation of novel
anti-inﬂammatory drugs is vital, as inﬂammation in COPD is
resistant to the effect of ICS monotherapy [58]. In this review we
will focus on phosphodiesterase-4 (PDE4) inhibitors, chemokine
antagonists and p38 mitogen-activated protein kinase (MAPK) in-
hibitors, which represent the most promising classes of anti-
inﬂammatory drugs currently in development for the treatment
of COPD.
4.2. PDE4 inhibitors
PDE4 is a speciﬁc phosphodiesterase predominantly expressed
by inﬂammatory cells, including those important to the patho-
genesis of COPD, which makes it an attractive target for the
development of new drugs [98]. PDE4 inhibitors are effective anti-
inﬂammatory agents in animal models and have been shown to
reduce markers of inﬂammation in COPD [99,100].
Roﬂumilast is an oral PDE4 inhibitor approved in the EU and in
the US for patients with severe COPD and a history of exacerbations
[101]. The efﬁcacy and safety of roﬂumilast alone or in combinationwith a long-acting bronchodilator (tiotropium or salmeterol) were
investigated in four long-term, large clinical trials [102e105].
Although in all these studies roﬂumilast signiﬁcantly improved
post-bronchodilator FEV1 compared with placebo, its effect on
exacerbations was inconclusive. Two post-hoc, pooled analysis of
trials involving patients with COPD, revealed that roﬂumilast
reduced exacerbation frequency in a subset of COPD patients with
chronic bronchitis, particularly in those taking concomitant ICS
[103,106]. Based on the results of these analyses, the effect of
roﬂumilast plus an ICS/LABA ﬁxed-dose combination on exacer-
bations will be investigated in a 1-year randomized, double-blind,
placebo-controlled Phase III/IV study [107].
Several inhaled PDE4 inhibitors are currently in development to
maximize efﬁcacy and reduce side effects associated with oral
administration [108]. GSK256066 demonstrated potent and long-
lasting anti-inﬂammatory effects in animal models of pulmonary
inﬂammation, with a low rate of gastrointestinal side effects [109].
A Phase II trial in COPD patients has recently been completed but no
data are currently available [110]. Despite the potential of
GSK256066, failures in clinical trials have been reported for other
inhibitors in development such as toﬁmilast [111].
PDE3 is important in mediating airway smooth muscle relaxa-
tion, as conﬁrmed by the observation that PDE3 inhibitors cause
bronchodilatation in subjects with asthma [112]. Combined PDE3/4
inhibitors, such as RPL554, could therefore have the ability to relax
airway smooth muscle and suppress inﬂammation and are
currently under investigation for the treatment of COPD. RPL554
has been shown to exhibit a broad range of both bronchoprotective
and anti-inﬂammatory activities in animalmodels [113]. The results
of a Phase II clinical trial in COPD patients have recently become
available and showed that a single dose of nebulized RPL554 pro-
duced a rapid bronchodilator response, with increase in FEV1
signiﬁcantly greater than that obtained with placebo and equiva-
lent to that achieved with the active comparator salbutamol [114].
In addition, RPL554 was well tolerated and did not cause any sig-
niﬁcant adverse effects.
New approaches in development to target PDE enzymes also
include oligonucleotide therapy, which aims at reducing protein
expression levels by targeting messenger RNA [115]. Several oli-
gonucleotides are currently in late preclinical or clinical stage
development for the treatment of COPD.
4.3. Chemokine antagonists
Expression of several chemokines is increased in patients with
COPD; this has generated a lot of interest in developing small-
molecule chemokine receptor antagonists [116,117]. Chemokines
secreted by activated macrophages play a pivotal role in inﬂam-
mation as they recruit neutrophils and monocytes to the lungs,
thereby amplifying the inﬂammatory response [82]. CX chemokine
receptor 2 (CXCR2) is expressed by monocytes and neutrophils and
mediates the activity of secreted chemokines such as CXCL1, CXCL5,
CXCL7 and CXCL8 [82]. Interestingly, CXCR2 has been found to be
up regulated in bronchial biopsies of patients with COPD with se-
vere exacerbations [118]. Two oral CXCR2 inhibitors, SCH527123
and SB656933, are in early clinical development. Studies in healthy
volunteers have demonstrated that both inhibitors caused attenu-
ation of ozone-induced neutrophil recruitment to the lungs and
displayed good tolerability proﬁles [119,120]. Moreover, SB656933
had also an effect on peripheral blood neutrophils and inhibited
agonist (CXCL-1)-mediated expression of the integrin CD11d, which
enables transmigration of circulating neutrophils into the lung
parenchyma [120]. A clinical trial in patients with asthma has
recently shown that SCH527123 was well tolerated and effective in
reducing sputum neutrophils [121]. A study evaluating the safety
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severe COPD has been completed although data are not currently
available [122].
CX chemokine receptor 3 (CXCR-3) and CX3C chemokine re-
ceptor 1 (CX3CCR1), which respectively mediate the recruitment of
T-lymphocytes and leukocytes in small airways and lung paren-
chyma, are also under investigation as new molecular targets in
COPD [123,124].
4.4. p38 MAPK inhibitors
The p38 MAPK family comprises four different isoforms (a, b, g
and d) that are activated in response to cellular stress [125]. The p38
MAPK pathway, which is activated in macrophages, CD8 lympho-
cytes and bronchial epithelial cells in patients with COPD [126,127],
regulates the expression of inﬂammatory cytokines including
CXCL8, TNF-a and MMPs, and therefore plays a key role in
inﬂammation [128,129]. In particular, p38a, the most important
isoform in the inﬂammatory response in COPD, is directly involved
in the migration of neutrophils and eosinophils into the lungs
[129e131]. Evidence suggests that inhibition of p38 MAPK kinase
pathway could potentially have therapeutic beneﬁts on many as-
pects of COPD, in addition to reducing the inﬂammatory response
that contributes to the pathogenesis of this disease. p38 MAPK
family mediates airway smooth muscle contraction and may also
contribute directly to the airﬂow limitation observed in COPD
[132e134]. Additionally, p38 MAPK activation has been shown to
contribute to corticosteroid insensitivity [135] and may play an
important role in mediating the effect of respiratory viruses, the
most common cause of exacerbations, on airways cells such as
macrophages and respiratory epithelium [136e138].
A number of small-molecule inhibitors of p38 MAPK have now
been developed. Although several oral p38 MAPK inhibitors have
been associated with liver toxicity, mainly due to off-target effects
[135], two novel compounds had encouraging efﬁcacy and safety
proﬁles in short-term studies in COPD. A single oral dose of the
p38a-selective inhibitor dilmapimod (SB681323) reduced the
levels of phosphorylated heat shock protein 27 (p-HSP27), a marker
of p38 MAPK activation, and TNF-a in whole blood derived from
patients with COPD [139]. A reduction in sputum neutrophils,
accompanied by an improvement in FVC but not in FEV1, was also
reported in a 4-week treatment using this compound [140]. In a 6-
week study different doses of PH797804, another inhibitor of p38a,
signiﬁcantly increased FEV1 with concomitant improvement in
dyspnea score and IC [141]. The efﬁcacy, safety and tolerability of
the oral Novartis inhibitor BCT197 are under evaluation in a ran-
domized, double-blind, placebo-controlled study in patients with
an acute COPD exacerbation [142].
Inhaled p38 inhibitors, are currently under development for the
treatment of COPD, with the aim of improving efﬁcacy and further
reducing systemic effects [143].
5. The future of COPD management: tailoring therapies to
phenotypes
It has now been recognized that COPD is a complex disease
characterized by multiple clinical manifestations with pulmonary
as well as extrapulmonary components [144]. Despite novel ther-
apies signiﬁcantly improving the standard of care in COPD in recent
years, a better understanding of the complexity of this disease at
molecular, cellular and clinical level is still needed to guide the
choice of therapy more effectively and allow patients to gain full
beneﬁts from new treatments.
Efforts have been ongoing in recent years to better characterize
the different phenotypes of COPD. In this context, a phenotype isdeﬁned as ‘a single or combination of disease attributes that
describe differences between individuals with COPD as they relate
to clinically meaningful outcomes’ [145].
Novartis is committed to identifying novel phenotypes in COPD
and is actively involved in several collaborations including
COPDGene, COPDMAP, SPIROMICS and the COPD Foundation
Biomarker Qualiﬁcation Consortium with the aim of identifying
underlying genetic factors, new clinical outcomes and biomarker in
COPD. This will allow the classiﬁcation of patients into distinct
subgroups and potentially drive the development of individualized
therapy, which could bematchedmore closely to patients’ needs, as
well as helping to further clarify the underlying pathophysiology of
COPD.6. Conclusions
Long-acting bronchodilators remain the cornerstone of the
management of symptomatic COPD. Given their importance in the
COPD treatment algorithm, Novartis has focused considerable
effort on developing novel once-daily dosing agents such as the
LABA indacaterol, the LAMA glycopyrronium and the LAMA/LABA
ﬁxed-dose combination QVA149, which have been shown to pro-
vide signiﬁcant beneﬁts to patients with COPD in terms of
improvement in lung function, exercise tolerance, health-related
quality of life, symptoms and reduction in the rate of exacerba-
tions. The new Novartis’ ICS/LABA combination QMF149, which is
in early clinical development, offers potential as a new treatment
option for patients at high risk of exacerbations. In order to ensure
continuity across the COPD Novartis portfolio, Novartis has further
invested signiﬁcant resources in developing the low-resistance,
dry-powder inhaler Breezhaler device, which represents a com-
mon platform for the delivery of all the COPD products.
Despite these recent advances in the treatment of COPD, there is
still a pressing medical need to develop new therapies targeted at
preventing disease progression and reducing mortality and exac-
erbations. In this context, targeting inﬂammation represents the
most promising approach; Novartis is fully committed to devel-
oping novel anti-inﬂammatory drugs able to address different as-
pects of the pathophysiology of COPD. Novartis is also actively
involved in several collaborations with the aim of gaining new in-
sights into the complexity of COPD and identifying novel COPD
phenotypes. This commitment is central to the achievement of
Novartis’ ﬁnal goal: developing innovative therapies in COPD to
improve patients’ lives.Acknowledgments
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